Use of MTX therapy at RA patients had a reduced effect on disease activity and inflammation, but the nonsignificance effect on the values of Apo B lipoproteins.
Keyphrases
- disease activity
- rheumatoid arthritis
- systemic lupus erythematosus
- end stage renal disease
- ankylosing spondylitis
- rheumatoid arthritis patients
- ejection fraction
- newly diagnosed
- chronic kidney disease
- juvenile idiopathic arthritis
- prognostic factors
- peritoneal dialysis
- bone marrow
- mesenchymal stem cells
- systemic sclerosis
- smoking cessation